Mochida Pharmaceutical Co., Ltd.
【Morita Pharmaceutical】Announcement of Executive Changes | June 25, 2026
Morita Pharmaceutical resolved to make executive changes at the Board of Directors meeting held on June 25, 2026, announcing new appointments and role changes. This includes changes in the representative director and directors, as well as the appointment of a candidate for auditing role.
Key Figures
- Representative director role change: Junichi Sakaki and Motoo Mitsuishi
- New officer candidate: Kenji Morita (overseeing Business Development)
- Auditor candidate: Reiko Nakano (Full-time auditor)
AI要約
Overview of Executive Changes
Morita Pharmaceutical resolved to implement executive changes at the Board of Directors meeting held on June 25, 2026, announcing role changes for the representative director and the appointment of new executives. Junichi Sakaki and Motoo Mitsuishi will continue to serve as representative directors, with Kenji Morita scheduled to be appointed as an officer overseeing Business Development. Role changes for directors and the appointment of candidates for auditors were also announced, aiming to strengthen management.
Future Outlook and Impact
These executive personnel changes are aimed at advancing Morita Pharmaceutical’s business strategy and strengthening governance, and will be officially confirmed after approval at the shareholders' meeting on June 25, 2026. The new structure is expected to enhance efficiency in R&D and business development, as well as improve management stability. For investors, the refreshing of management is regarded as part of the company's medium- to long-term growth strategy.
Morita Pharmaceutical Co., Ltd.
Company overview · Stock price · Financial data · All IR
